Share this post

Audience: This webinar is geared towards those involved with genomic variation analysis and interpretation of homologous recombination deficiency (HRD) from microarray data or next-generation sequencing (NGS) data in cytogenetics, molecular pathology, or molecular genetics labs.

Speaker information:

Dr. Christopher Lum, M.D.Dr. Christopher Lum, M.D.
Medical Director, Molecular Diagnostics Laboratory at Diagnostic Laboratory Services, Inc.
Zan Halford, M.S. SMB(ASCP)CM,
Medical Technologist, Diagnostic Laboratory Services, Inc.


NGS tumor profiling has become the mainstay of modern cancer therapy. Several NCCN-guided and FDA-approved therapies are currently on-market targeted by tumor genotype, and research is ongoing to identify other genomic alterations that can be used for stratification and drug development. This webinar describes an approach to genomic discovery that processes NGS data via NxClinical software from Bionano Genomics to assess solid tumors for genomic instability states associated with HRD.
Learning Objectives:
  • Be able to describe homologous recombination deficiency in the scheme of DNA damage and its role in cancer therapy, focusing on high grade ovarian epithelial cancers
  • Summarize the method of software solutions to view HRD genomic scars and describe the scoring method of HRD assessment
  • Describe the performance and limitations of NGS data in measuring chromosomal structural variants